Introduction
Genetically engineered replication-competent human adenoviruses (Ad), 1 like ONYX-015, 2, 3 are being tested in clinical trials as therapeutic tools to treat cancer. [4] [5] [6] To increase the oncolytic capabilities of the replicating Ads, we have developed an Armed Therapeutic Virus platform, where the lytic properties of the virus are coupled with the therapeutic benefit of virally delivered transgenes to better address the complexity of human cancers. 7 In the replicating adenovirus we have taken advantage of several properties of the Ad E3 region transcription unit to create an efficient replicating adenovirus-based gene delivery system. 8, 9 Ultimately, this system should allow investigators to create viruses that deliver multiple transgenes at predictable times and levels through the course of the viral infection. One of the regions of the E3 transcription unit, the E3B region ( Figure 1 ) encodes three proteins; two of the three genes form the RID (receptor internalization and degradation) complex, composed of RID␣ (10.4 K) and RID␤ (14.5 K), respectively. This complex protects the infected cell from lysis by TNF and Fas by clearing these receptors from the cell surface. 10 RID also clears other receptors from the cell surface including EGF-R. [10] [11] [12] The third gene in E3B encodes a protein known as 14.7 K that also protects the cell from TNF and has been shown to bind to a variety of proteins including FLICE. [13] [14] [15] We have previously demonstrated that therapeutic transgenes can be delivered predictably from the E3
Figure 1 Diagram of Ad5 E3 region depicting transgene insertion site. The arrow depicts the length of the E3 region; the hatched boxes below represent the known proteins that are synthesized in this transcription unit. The newly engineered sites are indicated above (ClaI and SwaI) with the star indicating the altered RID␣ start codon (see text). The transgene mTNF␣ was inserted as described, with the E3B proteins deleted, and this was constructed into the virus known as ONYX-321. The deletion in dl309 is similar to the sequences deleted in ONYX-321 (see text).
6.7 K/gp19 K region and the ADP region of a replicating human Ad. 8, 9 The substituted genes were expressed similarly to the genes they replaced and the remaining E3 genes continued to be expressed in keeping with the original hypotheses. In this study, the E3B region (deleted in ONYX-015) was genetically engineered so that it could be removed and replaced with the therapeutic transgene. TNF␣. TNF␣ is a pro-inflammatory cytokine that has a variety of antitumor activities. It is cytotoxic to tumor cells, 16, 17 enhances expression of HLA antigens 18 and ICAM-1 19 on tumor cells, chemo-sensitizes, [20] [21] [22] and radio-sensitizes tumor cells 23 and can be lytic to the tumor vasculature. 24, 25 The major problem associated with utilizing TNF as an anti-cancer therapy has been its systemic toxicities. Several laboratories have recently reported, however, promising data utilizing TNF in limb perfusion studies which limit systemic exposure. 22, [26] [27] [28] [29] [30] [31] [32] [33] Consequently, coupling TNF expression to a replicationselective Ad should limit its expression to the infected tumor, reducing systemic toxicity and increasing its therapeutic effectiveness alone or in combination therapies.
In this study, we generated a recombinant Ad (ONYX-321) that replaces the E3B region with the TNF␣ gene in an Ad5 background (Figure 1 ). We show that TNF is expressed and processed efficiently. However, unlike the native E3B genes, its expression occurs exclusively during the late phase of the viral infection.
Results mTNF and E3 protein expression
One of the advantages to using the endogenous gene expression machinery and substituting for endogenous genes should be that gene expression timing and protein levels are predictable. In this case, however, the prediction is complicated by the fact that several adenovirus genes are removed and replaced with a single therapeutic transgene. To ask how the timing of expression of mTNF from ONYX-321-infected cells compared with expression of endogenous E3B proteins, cell lysates of ONYX-321 and the wild-type Ad5-infected cell were analyzed by Western blot analysis for TNF␣, and RID␤ and 14.7 K expression, respectively. The RID␤ protein was detectable as early as 8 h p.i. (Figure 2a ) with 14.7 K expression slightly delayed and detectable by 12 h p.i. (Figure 2b) .
The cytokine mTNF exists as a plasma membranebound 26 kDa molecule which is cleaved to the extracellular form of 17.5 kDa. 34 To determine both the time of expression and processing of the TNF proteins, Western blots were performed from both cellular lysates and from the infected cell culture medium. Figures 2c and d demonstrate that mTNF expressed from the ONYX-321-infected cell was present in the expected forms and was therefore properly processed and cleaved. Interestingly, both the cell-associated and extracellular forms of mTNF from ONYX-321-infected cells can be detected by 24 h p.i. This is in contrast to the E3B genes, 14.7 K and RID␤, which were synthesized beginning around 8 to 12 h p.i. (Figure 2a 
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Western blot analysis was performed with lysates of Ad5, dl309 and ONYX-321-infected cells to determine if the expression of two of the remaining E3 genes, gp19 K and ADP, was altered in ONYX-321-infected cells. dl309 is an Ad5 derivative that has the E3B region deleted. This deletion extends from 30 005 to 30 750 and is substituted for by a 642 bp non-coding DNA fragment. 35 Western blot analysis of the E3 gp19 K protein (Figure 3a) demonstrates that dl309 and ONYX-321 synthesize gp19 K at times and levels similar to the parental Ad5. Interestingly, examination of the ADP protein expression levels revealed that it is overexpressed in ONYX-321 compared with Ad5 and dl309 (Figure 3b ). The reason for its overexpression is unknown. It may be related to mTNF expression, however, other recombinant Ads expressing mTNF do not overexpress ADP. 8, 9 Alterations in splicing, polyadenylation signal usage and mRNA levels are being explored.
Quantification of mTNF from ONYX-321-infected cells
To quantify the levels of mTNF secreted from ONYX-321-infected cells, an ELISA assay was utilized. The culture medium was changed 1 h before the designated timepoint and replaced with fresh medium. After 1 h, aliquots were removed and production of mTNF measured. This was done to measure de novo mTNF synthesis at the specific time-point in the course of the viral infection. mTNF levels from ONYX-321-infected cells peaked at 36 h p.i., reaching values close to 300 ng/million cells/h ( Figure  4 ). This quantity is much higher than that produced by mTNF insertion into other regions of the virus or when compared with a non-replicating Ad. 8, 9 mTNF is expressed as a late protein from ONYX-321 mTNF from ONYX-321 was not detected until 24 h p.i. (Figure 2c and d). This suggested that perhaps this protein was being expressed as a late viral gene in contrast to the replaced native E3B genes, which are expressed during the early phase of the viral infection. To examine this possibility further, cells were infected with ONYX-321 in the absence or presence of araC, an inhibitor of viral DNA replication. In the presence of araC, late gene expression should not occur. 8, 9 In contrast, an early protein like E3 gp19 K, whose expression is independent of viral DNA replication, should not be affected. As predicted, the expression of the early gp19 K protein in the ONYX-321-infected cells was not altered by the presence of araC, as detected by Western blot analysis (Figure 5a ). However, mTNF expression from the E3B region is not detected in the presence of araC by Western blot analysis, suggesting that its expression is limited to the late phase of the viral infection. Synthesis of two other late proteins, ADP and pVIII, was also blocked by the presence of araC in the ONYX-321-infected cells (data not shown). Consequently, mTNF expression from the E3B region is dependent upon DNA replication and therefore should be classified as a late gene in the context of this viral construct.
The E3B genes have been previously described as early genes and it was not predicted that their substitution would result in the mTNF gene being expressed with late gene kinetics. To understand this result better, we examined the expression of E3B RID␤ and 14.7 K proteins in the presence or absence of araC from wild-type Ad5-infected cells. In Figure 5c , gp19 K expression was not altered by the presence or absence of araC in the Ad5-infected cells, consistent with the gp19 K analysis generated from the ONYX-321-infected cells (Figure 5a ). In contrast, the expression of the E3B genes RID␤ and 14.7 K was dramatically altered by the presence of araC ( Figure  5d and e, respectively). This suggests that these genes, like the substituted mTNF gene, are highly dependent upon DNA replication for their expression. Interestingly, we do see some expression of the RID␤ and 14.7 K genes during the early phase, albeit markedly reduced relative to the late phase expression. As previously described, 9 the absence of TNF at early times after infection may be due to the potential detection limitations of the TNF antibody in the Western blot analysis and leaves open the possibility that minor levels of mTNF are expressed at early times p.i. Additional mutant viruses encoding different therapeutic transgenes in the E3B region are being generated to test this possibility. However, the quantification by ELISA as described above is sensitive to the picomolar range; therefore, we believe that the data from the Western blot analysis represent the translation of mTNF and is limited to the late phase of infection.
mTNF from ONYX-321 is functional
To determine if the mTNF secreted from ONYX-321-infected cells was biologically functional, a standard L929 cytotoxicity assay was performed. Conditioned culture medium from ONYX-321-infected cells was collected at 36 h p.i. and the mTNF level was determined by ELISA. The mTNF containing conditioned medium from ONYX-321-infected cells and commercially available recombinant mTNF (rmTNF) were diluted to the values indicated ( Figure 6 ) and exposed to susceptible L929 cells. The L929 cells were all killed at 0.5 ng/ml and partially killed at 0.05 ng/ml using the conditioned media from ONYX-321-infected cells (Figure 6b ) and paralled the results using the rmTNF (Figure 6a) . Therefore, the mTNF produced from ONYX-321-infected cells is biologically functional.
mTNF expression from ONYX-321 does not inhibit viral replication TNF is a pro-inflammatory molecule that can have deleterious effects on virally infected cells. To determine whether virally expressed TNF altered the virus's ability to replicate, cells were examined both for their ability to induce viral cytopathic effects (CPE) and for their ability to generate progeny virus. A549 cells were infected with Ad5, dl309, or ONYX-321 at an MOI of 10. At the indicated times p.i., the infected cells were photographed for comparison as seen in Figure 7 . Virally induced CPE appeared to be slightly faster in dl309 (E3B − ) and ONYX-
Figure 5 Transgene expression from the E3B region is dependent on DNA replication. A549 cells were infected at an MOI of 10 with either ONYX-321 (a and b) or Ad5 (c, d and e). Beginning at 4 h p.i., cells were left untreated or treated with araC, and then harvested at the indicated times p.i. Western blots were performed as described in the text for gp19 K (a and c), mTNF (b), RID␤ (d), or 14.7 K (e).

Figure 6 Murine TNF produced by ONYX-321 kills susceptible cells. L929 cells, a cell line known for its sensitivity to mTNF, was seeded in a 12-well plate and treated with either rmTNF (a) at the indicated concentrations or diluted conditioned medium from ONYX-321-infected cells (b) for 24 h. The cells were fixed and stained with crystal violet as described. For the conditioned culture medium used in panel b, A549 cells were infected at an MOI of 10 with ONYX-321 and, at 36 h p.i., an aliquot of the medium was removed. The mTNF present was quantified by ELISA and then diluted to the values indicated above the wells (b). ActD only indicates that only actinomycin D was added to the L9929 cells. Ad5 indicates that conditioned medium from Ad5-infected cells was used.
(E3B
−
, mTNF) as compared with Ad5 (wtE3B); this result was consistent over several independent experiments. The dl309-and ONYX-321-infected cells appeared to round up and detach from the plate slightly faster so that by 48 h p.i., the majority of cells were floating. In contrast, the Ad5-infected cells showed a significant amount of rounding up but the majority of the cells were still attached to the dish. These results suggest that an E3B-deleted virus may have a growth advantage over the wild-type virus. The presence of the E3B gene complex RID has been reported to negatively affect E1A protein expression 36 and may play a role in the observed CPE phenotype of the E3B-deleted viruses. Further experiments are planned to address this observation more rigorously.
To ask whether the deletion of the E3B region and insertion of the mTNF transgene altered the virus's capacity to replicate, burst assays were performed on
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Ad5, dl309, and ONYX-321-infected cells to quantify virus production. As seen in Figure 8 , the viral yield from these viruses were similar, with lower levels of virus being generated by the mTNF expressing ONYX-321-infected cells at the 48 h time-point.
Discussion
In this study, we have characterized another site in the Ad5 E3 region that can be utilized for gene delivery from a replicating Ad. In this case, a combination of genes which constitute the E3B region were taken out and replaced with a therapeutic transgene, mTNF␣. This region was specifically targeted for examination because it is also deleted in the clinical candidate virus, ONYX-015. Replacing the three E3B genes, RID␣/␤ and 14.7 K, with the cytokine mTNF, we have shown that the virally expressed mTNF is properly processed (Figure 2c and d) 
Figure 8 Burst assay. A549 cells were infected at an MOI of 10 with Ad5, dl309, or ONYX-321 as described. At 24 and 48 h p.i., the cells and medium were collected and the resulting quantity of infectious virus was determined as described and values normalized on a per cell basis.
and biologically functional ( Figure 6 ). We have demonstrated that synthesis of this molecule occurs to very high levels (Figure 4 ) from the virus when compared with other areas of the E3 region, 8, 9 and that expression occurs with classical late gene kinetics (Figure 5b) . Importantly, while TNF␣ has antiviral activity, its expression in vitro from the replicating Ad did not compromise the virus's ability to induce classical CPE in infected cells (Figure 7 ) or abolish the ability of the virus to produce progeny virus (Figure 8 ). In addition, the deletion of the E3B genes adds valuable genome space to insert additional therapeutic transgenes or to allow the insertion of a larger transgene. Given the packaging limitations of the replicating Ad, these are important considerations. 37 One premise of the gene delivery system was that the insertion of therapeutic transgene(s) could be done in a precise fashion to retain the expression of the surrounding E3 genes. In ONYX-321, the expression of the remaining two E3 genes, gp19 K and ADP, showed that these genes are expressed with normal kinetics (Figure 3) . The retention of the E3 gp19 K gene may benefit viral replication by blocking adenovirus-specific CTL-mediated destruction of the infected cell to allow completion of the replication cycle. 38 Retaining expression of the ADP gene should ensure efficient and timely lysis of the infected cell. 39, 40 It is also possible that these E3 genes may be nonessential in the virus-based treatment. For example, human tumors appear to have various properties associated with them to evade CTL-mediated clearance, making the presence of the gp19 K protein redundant. 8 Retaining the expression of the gp19 K then creates an opportunity potentially to replace this gene with another therapeutic transgene, utilizing the unique expression kinetics of gp19 K gene in combination with other therapeutic transgene to generate an even more robust therapeutic virus treatment. 7 Also, the expression of ADP may be dispensable since cells infected with viruses deleted in ADP will still undergo lysis, albeit at a later time. 9, 39, 40 This then allows another region for transgene insertion with expression kinetics that differ from that of the 6.7 K/gp19 K region or the E3B region. 8, 9 Expression from the E3B region has several properties of potential interest to investigators. The level of mTNF produced from the E3B region in ONYX-321 is very high compared with expression from the E1B-55 K region (manuscript in preparation) or to other sites in the E3 region. 8, 9 The reason for this is unclear. It is possible that this is a reflection of the total protein expression of the three E3B region genes (RID␣/␤ and 14.7 K) concentrated to a single gene. Alternatively, this may reflect a cascade of events that culminates in enhanced E3 gene transcription via TNF␣ and its activation of the transcription factor, NF-B. In this scenario, the interaction between TNF and its receptor results in activation of NF-B, a known TNF-inducible transcription factor. 41, 42 This should enhance gene expression from the E3 promoter which contains two NF-B binding sites. 43 Consequently, enhanced expression may be a result of the transgene chosen and its interaction with the E3 promoter. Since these hypotheses are not mutually exclusive, it is possible that components of each may be contributing to the marked expression levels noted from this region. Further analysis is being conducted to address this issue.
Transgene expression of mTNF from the E3B region occurred exclusively during the late phase of the viral infection. This was also seen for mTNF expression from the ADP region. In the ADP case, another therapeutic transgene inserted into the ADP region, the bacterial prodrug converting cytosine deaminase, showed minor levels of expression at early time p.i. This points to the possibility that minor levels, undetectable by the mTNF antibodies, are being expressed and further analysis with additional therapeutic transgenes will be necessary to address this issue more completely. Regardless, this late gene expression pattern creates an opportunity for transgene expression to be directly linked to the tumor selectivity of viral infection. For example, if the tumor-selective mechanism of the virus is dependent on early events in the viral infection (viral attachment, penetration, early promoter activation and gene expression), viral DNA replication should not occur and therefore the therapeutic transgene should not be expressed. In the appropriate target tumor cell, viral DNA replication should occur and result in the expression of the therapeutic transgene. This option for tighter tumor-specific transgene expression control becomes an even more important consideration when the virus is delivered intravenously as a means to target distant metastasis.
In summary, we have shown that gene delivery can occur from the E3B region of a replicating Ad. Replacing the E3B region with the cytokine gene TNF, we have achieved very high expression levels, which appear to be restricted to the late phase of the infection, and retained expression of the two remaining E3 gene products, gp19 K and ADP. In the accompanying articles, we have demonstrated that the other areas of E3 can also be utilized for gene delivery. By combining multiple transgenes in a single tumor-selective virus, we can create a more powerful system to treat cancer.
Materials and methods
Cells and viruses
The cell lines A549 and L929 and parent virus Ad5 were described previously. 8, 9 The virus dl309 was generously provided by Dr William SM Wold, St Louis University; MO, USA.
Shuttle vector construction
The parent plasmid pSN has been described previously. 8 To replace the E3B region, the restriction endonuclease sites ClaI and SwaI were engineered at nucleotides 29 862 and 30 830, respectively, and this plasmid was called pSN-CS. (All numbering refers to the Ad5 genome nucleotides, accession No. M73260). The primers 5Ј ClaI (CACATCGATGTAGACTGC) and 5ЈSwaI (CTCAAAG ATCTTATTCCATTTAAATAATAAA) were used for PCR mutagenesis as previously described. 8, 9 The ClaI site was engineered downstream of the translation start site Gene Therapy for RID␣ because of the presence of splicing control elements in that region. 44 Therefore, the RID␣-ATG initiation codon was mutated as to not allow preventative translation initiation using the primer 5ЈEcoRV (GATT AAATGAGATATCATTCCTCGAG) in PCR mutagenesis. This mutation also added an EcoRV restriction site; this plasmid is referred to as pSN-CS+V.
The mTNF gene was obtained from ATCC (as previously described) and was amplified by PCR to create a 5Ј ClaI restriction enzyme site and a 3Ј SwaI restriction enzyme site. Both the vector pSN-CS and the amplified mTNF gene were cut with ClaI and SwaI (all enzymes Roche Molecular Biochemicals, Indianapolis, IN, USA) and the gel purified (Qiagen gel extraction kit; Qiagen, Santa Clara, CA, USA) fragments were ligated together. After transformation, colonies were screened and sequenced for the correct construct and to ensure no PCR-mediated mutations had occurred. This plasmid was marked pSN-CS+V-mTNF.
Virus construction on ONYX-321
Ad5 containing the mTNF gene in the E3B region was constructed by homologous recombination as described previously, 8 with the following modifications. Instead of Ad5 TP-DNA, the ONYX-300 TP-DNA was used. This virus contains a deletion of the ADP gene plus a unique BstBI restriction site at 29 355. 9 This was cut with BstBI while the plasmid pSNCS+V-mTNF was cut with SpeI and NdeI. The gel-purified fragment containing the mTNF gene in the E3B region was combined with the BstBI-restricted ONYX-300 9 TP-DNA and this mixture was directly used to transfect A549 cells as described previously. 8 Viral plaques were picked, screened, purified, and sequenced as described previously. 8, 9 Infections and Western blot analysis A549 cell lysates were created and Western blot analysis was performed as described previously. 8, 9 The collection of conditioned medium and the araC treatment were also performed as previously described. 8, 9 mTNF ELISA, burst assay, and L929 cell killing assay All assays were performed as previously described. 8, 9 
